Leo Pharma acquires the rights to develop psoriasis treatment outside Europe

Leo Pharma, who have under an agreement with Astra Zeneca, successfully launched psoriasis treatment brodalumab in 18 countries, have acquired the rights to develop and market the treatment outside of Europe.
With around 125 million people living with psoriasis around the globe, Leo will be able to market the treatment into countries include Australia, Brazil, Egypt Mexico and Saudi Arabia, where there is a higher need for the treatment, thanks to a new agreement with Bausch Healthcare, Ireland Limited.
“Living with psoriasis is often underestimated.” Said president and CEO of LEO Pharma Catherine Mazzacco. “This new agreement allows us to bring in a new option to many more who suffer with psoriasis across the globe, and underlines out commitment to expand our successful dermatology portfolio.”
Baush Health retains the rights to develop and market to brodalumab within Canada and the US.